ProShare Advisors LLC Sells 758 Shares of BioNTech SE Sponsored ADR $BNTX

ProShare Advisors LLC decreased its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 16.9% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,730 shares of the company’s stock after selling 758 shares during the quarter. ProShare Advisors LLC’s holdings in BioNTech were worth $397,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of BNTX. Profund Advisors LLC boosted its holdings in BioNTech by 3.6% during the 2nd quarter. Profund Advisors LLC now owns 4,309 shares of the company’s stock valued at $459,000 after acquiring an additional 149 shares during the period. Fox Run Management L.L.C. purchased a new stake in shares of BioNTech during the second quarter valued at $303,000. Bank of New York Mellon Corp grew its holdings in shares of BioNTech by 58.8% in the second quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock worth $118,045,000 after purchasing an additional 410,351 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in shares of BioNTech by 472.0% in the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock worth $61,000 after purchasing an additional 472 shares during the last quarter. Finally, Howard Capital Management Inc. purchased a new position in BioNTech in the 2nd quarter worth about $221,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wells Fargo & Company set a $150.00 target price on shares of BioNTech and gave the stock an “overweight” rating in a research note on Tuesday, August 5th. Bank of America lowered their price target on BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, October 22nd. UBS Group increased their price objective on BioNTech from $115.00 to $117.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a research report on Monday. Finally, JPMorgan Chase & Co. lowered their target price on BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a report on Thursday, October 23rd. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $135.20.

BioNTech Stock Performance

Shares of NASDAQ:BNTX opened at $96.97 on Friday. The firm has a 50 day moving average of $102.78 and a 200 day moving average of $104.86. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $23.32 billion, a price-to-earnings ratio of -60.61 and a beta of 1.54. BioNTech SE Sponsored ADR has a 52 week low of $81.20 and a 52 week high of $129.27.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.89). The company had revenue of $1.78 billion for the quarter, compared to the consensus estimate of $1.21 billion. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm’s revenue was up 22.0% compared to the same quarter last year. During the same period last year, the business posted $0.81 EPS. BioNTech has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.